منتجو اللقاحات يحققون أرباحاً وفيرة
May 11, 2021 - The four front-running vaccine-makers have seen their profits surge since the rollout of coronavirus shots, boosted by some $18.5 billion from government, public and private funding.
In total, governments and not-for-profit organisations have provided $4.59 billion, according to science data analytics company Airfinity. Private funding has provided around $13.91 billion.
AstraZeneca/Oxford University has received over $11.5 billion, and Johnson & Johnson has scooped up $1.1 billion. Almost $3.2bn has gone to Pfizer/BioNTech, while Moderna has received $2.68 billion.
Pfizer expects 2021 revenue of between $44 billion and $46 billion, with profits of at least $14 billion, split 50-50 between Pfizer and its German partner BioNTech.
Moderna’s forecast for 2021 is for revenue of $16 billion, overwhelmingly from vaccine sales.
Johnson & Johnson has said it will provide the vaccine on a not-for-profit basis as long as the world continues suffering from the pandemic. However, even after the pandemic has passed, people will need to receive booster shots to protect themselves from new variants.